PUBLIC COMPANY
saveDaiichi Sankyo Co Ltd
updated 1mo ago
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
community read0 votes
pipeline
17
marketed
4
phase 3
2
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(17)
view full pipeline →pipeline depth17 products
3Phase 13Phase 22Phase 34Marketed3Unknown2pre_registration
Marketed
edoxaban tosylate
Atrial Fibrillation
Marketedpexidartinib hydrochloride
Tenosynovial Giant Cell Tumor
Marketedquizartinib dihydrochloride
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Marketedtrastuzumab deruxtecan
Metastatic Colorectal Cancer
Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1
Phase 3Upcoming
no upcoming catalysts on record
Recent(90d)
phase 1 completion (1) · patent expiry (1) · drug expiry (1) · approval (1)
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that